Considering there is evidence to suggest that subchronic L-DOPA administration can reduce the accumulation of central phosphorylated alpha-synuclein in the SNpc [75], future retinal studies quantifying and/or correlating electrophysiological and immunohistochemical outcomes in A53T mice following chronic L-DOPA treatment would contribute to strengthening our understanding of dopamine and alpha-synuclein’s synergistic interactions within the context of Parkinson’s disease. The gene discussed is SNCA; the disease is Parkinson disease.